EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Does Lymphovenous Anastomosis Effect Mammalian Target of Rapamycin Inhibitor-associated Lymphedema Patients?

Inah Yoon iD, Hyung Bae Kim iD, Jeongmok Cho iD, Changsik John Pak iD, Hyunsuk Peter Suh iD, Jae Yong Jeon iD, Joon Pio Hong iD

Archives of Plastic Surgery · 01.05.2024 · 51 (03) · 321-326

DOI: 10.1055/a-2201-5881 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Plastic Surgery, erschienen am 01.05.2024. Verfasst von Inah Yoon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic and Reconstructive Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mammalian target of rapamycin (mTOR) inhibitors are used to prevent organ transplant rejection and are preferred over other immunosuppressants due to its low nephrotoxicity. However, mTOR inhibitors have been associated with various adverse effects including lymphedema. Although rare in incidence, previously known treatments for mTOR inhibitor-induced lymphedema were limited to discontinuation of related drugs and complex disruptive therapy with variable results. In this article, three patients who developed lymphedema in their lower limbs after using mTOR inhibitors, including two bilateral and one unilateral case, were treated with physiologic surgery methods such as lymphovenous anastomosis (LVA) and lymph node transfer. The efficacy of the treatment was evaluated. In the three cases described, cessation of the drug did not lead to any reduction in edema. The use of LVA and lymph node transfer resulted in early reductions in volume but failed to sustain over time. All patients underwent secondary nonphysiologic surgery such as liposuction resulting in sustained improvement. This series presents the first physiologic approach to mTOR inhibitor-induced lymphedema. Although further study is warranted, the physiologic surgical options may have limited success and nonphysiologic options may offer better sustainable results.

Schlagwörter

Stichwörter der Autor:innen

immunosuppressive agentslipectomylymphedemamTOR inhibitorssirolimus

Autor:innen und Institutionen

  • Department of Plastic and Reconstructive Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Rehabilitation Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

ORCID-Profile: Inah Yoon, Hyung Bae Kim, Jeongmok Cho, Changsik John Pak, Hyunsuk Peter Suh, Jae Yong Jeon, Joon Pio Hong

Zitieren

APA

Yoon, I., Kim, H. B., Cho, J., Pak, C. J., Suh, H. P., Jeon, J. Y., & Hong, J. P. (2024). Does Lymphovenous Anastomosis Effect Mammalian Target of Rapamycin Inhibitor-associated Lymphedema Patients?. Archives of Plastic Surgery, 51(03), 321-326. https://doi.org/10.1055/a-2201-5881

Vancouver

Yoon I, Kim HB, Cho J, Pak CJ, Suh HP, Jeon JY, et al. Does Lymphovenous Anastomosis Effect Mammalian Target of Rapamycin Inhibitor-associated Lymphedema Patients?. Archives of Plastic Surgery. 2024;51(03):321-326. doi:10.1055/a-2201-5881

BibTeX
@article{Yoon2024,
  author = {Yoon, Inah and Kim, Hyung Bae and Cho, Jeongmok and Pak, Changsik John and Suh, Hyunsuk Peter and Jeon, Jae Yong and Hong, Joon Pio},
  title = {Does Lymphovenous Anastomosis Effect Mammalian Target of Rapamycin Inhibitor-associated Lymphedema Patients?},
  journal = {Archives of Plastic Surgery},
  year = {2024},
  volume = {51},
  number = {03},
  pages = {321--326},
  doi = {10.1055/a-2201-5881}
}
Kostenlos starten →